Paper Details

  1. Home
  2. Paper Details

Respiratory syncytial virus prevention: past and present strategies.

Author: GreenoughA, ThomasM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Respiratory syncytial virus (RSV) is a common cause of respiratory illness in young children. Immunoprophylaxis with RSV immunoglobulin or palivizumab is recommended for high-risk infants. Palivizumab is the preferred agent due to its better safety profile.
Paper Details　
Original Abstract of the Article :
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in young children, almost all will have been infected by the age of two years old. Very young infants, and those with underlying disease, are at risk of severe RSV disease, but even those who were previously healthy can suffe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14656566.1.6.1195

データ提供：米国国立医学図書館（NLM）

Respiratory Syncytial Virus (RSV): A Common Childhood Threat

Respiratory syncytial virus (RSV) is a common respiratory virus that infects almost all children by the age of two. While most infections are mild, RSV can cause severe respiratory illness in infants, particularly those with underlying health conditions. This review examines the past and present strategies for preventing RSV infection.

The authors discuss the challenges of developing an effective RSV vaccine and the importance of immunoprophylaxis, using antibodies to prevent infection. While standard immunoglobulin is ineffective against RSV, RSV immunoglobulin (RSV-IGIV) and a humanized monoclonal antibody (palivizumab) have shown promising results in reducing hospitalizations in high-risk infants. The researchers emphasize the need for careful patient selection and cost-effectiveness considerations when using these immunoprophylactic agents.

Protecting Infants from RSV

This review highlights the importance of preventing RSV infection in high-risk infants. The authors discuss the effectiveness of immunoprophylaxis and the need for careful patient selection to maximize benefits and minimize costs. The research underscores the ongoing need for new and improved strategies for preventing RSV infection.

Navigating the Landscape of RSV Prevention

This review provides a valuable overview of the current strategies for preventing RSV infection. It highlights the challenges and successes of different approaches, offering insights into the ongoing search for a safe and effective RSV vaccine. The research emphasizes the importance of continued research and development in this area to better protect vulnerable infants from the complications of RSV infection.

Dr. Camel's Conclusion

RSV is like a desert sandstorm, capable of causing respiratory distress in infants. This review is a guide to navigating the landscape of RSV prevention, helping us find ways to shield vulnerable infants from this common childhood threat.

Date :
  1. Date Completed 2001-04-05
  2. Date Revised 2019-09-15
Further Info :

Pubmed ID

11249487

DOI: Digital Object Identifier

10.1517/14656566.1.6.1195

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.